Home › NDC Lookup › Ingredients › Omeprazole › 71335-0569-07
Omeprazole 20 mg Capsule, Delayed Release, 120-count — NDC 71335-0569-07 package photo

Omeprazole 20 mg Capsule, Delayed Release, 120-count

by Bryant Ranch Prepack · 120 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-7)
NDC 71335-0569-07
🏷️ FDA NDC (as labeled) 71335-0569-7 billing pads the package segment with a zero
This package
Contains120-count Pack sizes10 compare ↓
Also priced by: Part D plans $0.2027/unit — full pricing hub ↓
Also comes in: 7 capsules 71335-0569-00 15 capsules 71335-0569-06 20 capsules 71335-0569-05 28 capsules 71335-0569-09 30 capsules 71335-0569-01 56 capsules 71335-0569-03 60 capsules 71335-0569-02 90 capsules 71335-0569-04 100 capsules 71335-0569-08
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Omeprazole (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 30, 2025 — Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules. (Dr. Reddy's Laboratories, Inc.) · FDA recall D-0525-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 71335-0569-7
Product NDC 71335-0569
11-digit billing NDC 71335056907
NCPDP billing unit EA — each (per item)
RxCUI 198051, 200329
UNII KG60484QX9
Application # ANDA076048
SPL Set ID 44349466-73ea-4053-8ff6-5b4b7372c9cd
Established class (EPC) Proton Pump Inhibitor
Mechanism of action Proton Pump Inhibitors; Cytochrome P450 2C19 Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2003-11-11
Marketing end 2027-01-31
Route ORAL
Dosage form CAPSULE, DELAYED RELEASE
Substance OMEPRAZOLE
GPI-14 49270060006520
GPI class Omeprazole
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 71335-0569-7 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 71335-0569-07. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Proton Pump Inhibitor class.

Pharmacologic class Proton Pump Inhibitor
Drug family (ATC) Proton pump inhibitors
How it works Proton Pump Inhibitors, Cytochrome P450 2C19 Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerBryant Ranch Prepack
Application holderAPOTEX INC
FDA applicationANDA076048 (ANDA)
Labeler code71335
First marketedNov 2003
Product typeHuman Prescription Drug
Portfolio4,433 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

📖 What it is MedlinePlus · NLM

Prescription omeprazole is used alone or with other medications to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Prescription omeprazole is used to treat damage from GERD in adults and children 1 month of age and older. Prescription omeprazole is used to allow the esophagus to heal and prevent further damage to the esophagus in adults and children 1 year of age and older with G...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Omeprazole turns down your stomach's acid production by blocking the pump that makes acid in the first place. Depending on why you're taking it, that can mean relief from heartburn...
  • What exactly is omeprazole supposed to do for me?
  • Take it about 30 minutes before a meal, ideally before breakfast. Taking it before eating gives it the best chance to be absorbed and ready to work when your stomach starts produci...
  • When should I take it — before or after eating?
📖 Read our full Omeprazole guide →
9
Nutrient depletion considerations

Omeprazole may be associated with lower levels of 9 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Omeprazole nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color Pink / Brown
ShapeCapsule
ImprintAPO;040
Size21 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3K9958V90M
    A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
  • UNII 5138Q19F1X
    Ammonia is a colorless gas made from nitrogen and hydrogen. It's used in medicines as a pH buffer to maintain the correct acidity level and help keep the product stable.
  • UNII 8PJ61P6TS3
    Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
  • UNII 1K09F3G675
    Ferric oxide red is an inorganic iron compound used as a colorant in medicines. It gives tablets, capsules, or other dosage forms a red or reddish tint for identification and appearance.
  • UNII XM0M87F357
    A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII ND2M416302
    Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
  • UNII NBZ3QY004S
    Magnesium hydroxide is a mineral compound that acts as a buffer and pH adjuster in medications. It helps neutralize stomach acid and keeps the medicine at the right acidity level for stability and absorption.
  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII NX76LV5T8J
    A synthetic plastic polymer made from methacrylic acid and ethyl acrylate. It's used as a coating or binder to control how and where the medicine dissolves in your digestive system.
  • UNII WZH3C48M4T
    Potassium hydroxide is a strong alkaline chemical used in medicines to adjust and maintain the pH level of liquid formulations, helping keep the product stable and the active ingredients effective.
  • UNII U725QWY32X
    Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 46N107B71O
    Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII 8Z96QXD6UM
    Triethyl citrate is a clear liquid derived from citric acid. It acts as a plasticizer and solvent in tablet coatings and film formulations, helping the coating remain flexible and adhere properly to the medicine.

16 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.2027 $24.32 / 120 capsules
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Omeprazole 20 mg 00904-6917-61 Major 1 capsule $0.028 AB Availability likely —
Omeprazole 20 mg 16714-0634-01 NorthStar 30 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 16714-0715-01 NorthStar 30 capsules $0.028 AB Discontinued —
Omeprazole 20 mg 55111-0158-01 Dr. 100 capsules $0.028 — Availability likely —
Omeprazole 20 mg 55111-0644-01 Dr. 100 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 60505-0065-00 Apotex 30 capsules $0.028 AB Discontinued —
Omeprazole 20 mg 60687-0597-01 American 1 capsule $0.028 AB Availability likely —
Omeprazole 20 mg 68084-0128-01 American 1 capsule $0.028 AB Discontinued —
Omeprazole 20 mg 68382-0412-01 Zydus 100 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 68462-0396-01 Glenmark 100 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 82009-0022-10 Quallent 1000 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 82009-0183-10 Quallent 1000 capsules $0.028 AB Availability likely —
Omeprazole 20 mg 00781-2868-01 Sandoz 100 capsules $0.029 AB Availability likely —
Omeprazole 20 mg 60505-3952-03 Apotex 30 capsules $0.034 AB Discontinued —
Omeprazole 20 mg 62175-0118-32 Lannett 30 capsules $0.036 AB FDA listed —
Omeprazole 20.6 mg 46122-0686-03 AMERISOURCE 14 capsules $0.408 — Discontinued —
Omeprazole Magnesium 20 mg 55111-0397-27 Dr. 14 capsules $0.408 — Availability likely —
Acid Reducer 20 mg 70000-0232-01 LEADER/ 14 capsules $0.408 — Availability likely —
Omeprazole Magnesium 20 mg 83324-0117-14 Chain 14 capsules $0.408 — Availability likely —
Omeprazole Magnesium 20 mg 00363-0042-01 Walgreens 14 capsules — — FDA listed —
Omeprazole 20 mg 00363-4099-03 Walgreen 14 capsules — — FDA listed —
omeprazole 20 mg 00363-6089-01 Walgreen 14 capsules — — FDA listed —
Omeprazole 20 mg 00363-9980-14 Walgreen 14 capsules — — FDA listed —
Omeprazole 20 mg 00615-8406-05 NCS 15 capsules — AB FDA listed —
Omeprazole 20 mg 00781-2790-01 Sandoz 100 capsules — AB FDA listed —
Omeprazole 20 mg 11673-0948-14 UP 14 capsules — — FDA listed —
omeprazole 20.6 mg 11822-0061-04 Rite 14 capsules — — FDA listed —
Omeprazole Magnesium 20 mg 21130-0398-33 Albertsons 14 capsules — — FDA listed —
omeprazole 20 mg 21130-0528-01 Safeway 14 capsules — — FDA listed —
Omeprazole 20 mg 21130-0783-01 Safeway 14 capsules — — FDA listed —
Omeprazole Magnesium 20 mg 30142-0012-01 The 14 capsules — — FDA listed —
omeprazole 20 mg 31722-0528-01 Camber 100 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 37808-0006-33 HEB 14 capsules — — FDA listed —
Omeprazole 20 mg 42708-0170-14 QPharma 14 capsules — AB FDA listed —
Omeprazole 20 mg 42708-0199-14 QPharma 14 capsules — AB FDA listed —
Omeprazole 20 mg 43063-0743-14 PD-Rx 14 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 43598-0813-14 Dr. 14 capsules — — FDA listed —
Omeprazole Magnesium 20 mg 49035-0397-27 Wal-Mart 14 capsules — — FDA listed —
Omeprazole 20 mg 49999-0265-14 Quality 14 capsules — AB Discontinued —
Omeprazole 20 mg 50090-1157-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-3876-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-5111-00 A-S 90 capsules — AB FDA listed —
Omeprazole 20 mg 50090-5901-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-5902-00 A-S 90 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7018-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7019-00 A-S 90 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7021-00 A-S 1 capsule — AB FDA listed —
Omeprazole 20 mg 50090-7213-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7214-00 A-S 100 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7215-00 A-S 90 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7472-00 A-S 30 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7473-00 A-S 100 capsules — AB FDA listed —
Omeprazole 20 mg 50090-7474-00 A-S 90 capsules — AB FDA listed —
Omeprazole 20 mg 51316-0061-28 CVS 28 capsules — — FDA listed —
omeprazole 20 mg 51316-0271-03 CVS 14 capsules — — FDA listed —
Omeprazole 20 mg 51316-0843-03 CVS 14 capsules — — FDA listed —
Omeprazole 20 mg 51407-0287-01 Golden 100 capsules — AB Discontinued —
Omeprazole 20 mg 51407-0641-00 Golden 1 capsule — AB FDA listed —
Omeprazole 20 mg 51407-0813-01 Golden 100 capsules — AB FDA listed —
Omeprazole 20 mg 51655-0061-25 Northwind 60 capsules — AB FDA listed —
Omeprazole 20 mg 51655-0893-25 Northwind 60 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 53943-0520-14 Discount 14 capsules — — FDA listed —
Omeprazole 20 mg 55154-2332-00 Cardinal 1 capsule — AB FDA listed —
Omeprazole 20 mg 57237-0161-01 Rising 100 capsules — AB FDA listed —
omeprazole 20.6 mg 57483-0740-42 INNOVUS 14 capsules — — FDA listed —
Omeprazole Magnesium 20.6 mg 57896-0759-14 Gericare 14 capsules — — FDA listed —
Omeprazole 20 mg 58602-0837-05 Aurohealth 14 capsules — — FDA listed —
Omeprazole 20 mg 59651-0002-01 Aurobindo 100 capsules — — FDA listed —
Omeprazole 20 mg 60760-0747-07 St. 7 capsules — AB FDA listed —
Omeprazole 20 mg 60760-0833-30 St. 30 capsules — AB FDA listed —
Omeprazole 20 mg 60760-0868-07 St. 7 capsules — AB FDA listed —
Omeprazole 20 mg 63187-0070-14 Proficient 14 capsules — AB FDA listed —
Omeprazole 20 mg 63187-0820-06 Proficient 6 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 63868-0177-15 Chain 14 capsules — — FDA listed —
Omeprazole 20 mg 65841-0760-01 Zydus 100 capsules — AB FDA listed —
Omeprazole 20 mg 67046-1509-03 Coupler 30 capsules — AB FDA listed —
Omeprazole 20 mg 67296-1939-03 Redpharm 30 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 68016-0760-14 Chain 14 capsules — — FDA listed —
Omeprazole 20 mg 68071-2243-07 NuCare 7 capsules — AB FDA listed —
Omeprazole 20 mg 68071-2262-03 NuCare 30 capsules — AB FDA listed —
Omeprazole 20 mg 68071-3007-02 NuCare 28 capsules — AB FDA listed —
Omeprazole 20 mg 68071-3733-02 NuCare 20 capsules — AB FDA listed —
Omeprazole 20 mg 68071-4024-03 NuCare 30 capsules — AB FDA listed —
Omeprazole 20 mg 68071-4025-03 NuCare 30 capsules — AB FDA listed —
Omeprazole 20 mg 68788-4104-01 Preferred 100 capsules — AB FDA listed —
Omeprazole 20 mg 68788-6881-01 Preferred 100 capsules — AB FDA listed —
Omeprazole 20 mg 68788-8805-01 Preferred 100 capsules — AB FDA listed —
Omeprazole 20 mg 68788-8864-01 Preferred 100 capsules — AB FDA listed —
Omeprazole Magnesium 20 mg 69842-0027-01 CVS 14 capsules — — FDA listed —
Omeprazole 20 mg 70518-2251-00 REMEDYREPACK 30 capsules — AB Discontinued —
Omeprazole 20 mg 70518-3278-00 REMEDYREPACK 30 capsules — AB Discontinued —
Omeprazole 20 mg 70518-4177-00 REMEDYREPACK 30 capsules — AB FDA listed —
Omeprazole 20 mg 70700-0150-00 Xiromed, 1 capsule — AB FDA listed —
Omeprazole 20 mg 71205-0613-14 Proficient 14 capsules — AB FDA listed —
Omeprazole 20 mg 71205-0907-00 Proficient 100 capsules — AB FDA listed —
Omeprazole 20 mg 71335-0332-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mgthis 71335-0569-07 Bryant 120 capsules — AB FDA listed —
Omeprazole 20 mg 71335-1636-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mg 71335-1746-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mg 71335-1852-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mg 71335-9609-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mg 71610-0663-30 Aphena 30 capsules — AB FDA listed —
Omeprazole 20 mg 71610-0912-30 Aphena 30 capsules — AB FDA listed —
Omeprazole 20 mg 71610-0942-30 Aphena 30 capsules — AB FDA listed —
Omeprazole 20 mg 71610-0963-60 Aphena 90 capsules — AB FDA listed —
basic care omeprazole 20 mg 72288-0023-03 Amazon.com 42 capsules — — FDA listed —
omeprazole 20 mg 72288-0606-03 Amazon.com 14 capsules — — FDA listed —
Omeprazole 20 mg 72789-0482-14 PD-Rx 14 capsules — AB FDA listed —
Omeprazole 20 mg 76420-0055-03 Asclemed 30 capsules — AB FDA listed —
Omeprazole 20.6 mg 79481-0061-03 Meijer 42 capsules — — FDA listed —
omeprazole 20 mg 79481-0281-00 Meijer, 14 capsules — — FDA listed —
omeprazole 20 mg 79481-3023-01 Meijer, 14 capsules — — FDA listed —
equate omeprazole 20 mg 79903-0112-14 WALMART 14 capsules — — FDA listed —
Omeprazole DR 20 mg 80425-0070-01 Advanced 30 capsules — AB FDA listed —
Omeprazole DR 20 mg 80425-0071-01 Advanced 30 capsules — AB FDA listed —
Omeprazole 20 mg 80425-0415-01 Advanced 30 capsules — AB FDA listed —
Omeprazole 20 mg 80425-0504-01 Advanced 30 capsules — AB FDA listed —
Omeprazole 20 mg 82868-0043-60 Northwind 60 capsules — AB FDA listed —
Omeprazole 20 mg 83209-0150-05 Boswell 5 capsules — AB FDA listed —
Omeprazole 20 mg 85509-1396-01 PHOENIX 120 capsules — AB FDA listed —
Omeprazole 20 mg 85509-1644-01 PHOENIX 120 capsules — AB FDA listed —
Omeprazole 20 mg 87441-0063-01 Unit 30 capsules — AB FDA listed —
Omeprazole 20 mg 71335-1639-00 Bryant 7 capsules — AB FDA listed —
Omeprazole 20 mg 85534-0036-00 HAWAII 30 capsules — AB FDA listed —
Omeprazole 20 mg 59640-0699-01 H 14 capsules — — FDA listed —
Omeprazole 20 mg 68071-5301-09 NuCare 90 capsules — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2003
On the market since
Nov 2003
📍
2026
Currently FDA-listed
23 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Omeprazole — the program that covers self-administered drugs. 14 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Omeprazole. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$75.01M
Claims incl. refills
7.1M
Beneficiaries
5.3M
Spend / beneficiary
$14.18
Spend / claim
$10.59
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Omeprazole — the ingredient across all brands.

Top reported reactions

Chronic Kidney Disease36,807
Nausea27,095
Fatigue26,259
Diarrhoea25,668
Acute Kidney Injury23,964
Dyspnoea21,145
Pain20,498

Age at onset

Neonate292
Infant271
Child706
Adolescent877
Adult32,838
Elderly30,558

Reporter sex

448,293 reports
Male · 40%
Female · 60%
Unknown · 0%

Serious outcomes

Hospitalization150,621
Death39,276
Life-threatening19,121
Disabling14,768
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 45,465 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
71335-0569-00 7 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-0) 2006-06-26 Active
71335-0569-01 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-1) 2006-06-26 Active
71335-0569-02 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-2) 2006-06-26 Active
71335-0569-03 56 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-3) 2006-06-26 Active
71335-0569-04 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-4) 2006-06-26 Active
71335-0569-05 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-5) 2006-06-26 Active
71335-0569-06 15 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-6) 2006-06-26 Active
71335-0569-07 You're viewing this 120 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-7) 2006-06-26 Active
71335-0569-08 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-8) 2006-06-26 Active
71335-0569-09 28 CAPSULE, DELAYED RELEASE in 1 BOTTLE (71335-0569-9) 2006-06-26 Active

You're viewing the largest of 10 pack sizes for this product.

Pack size FAQ

What quantity is in NDC 71335-0569-07?
NDC 71335-0569-07 is a 120-count package — 120 capsule, delayed release in 1 bottle.
What is the difference between NDC 71335-0569-07 and NDC 71335-0569-00?
Both are Omeprazole 20 mg Capsule, Delayed Release — the drug itself is identical. NDC 71335-0569-07 is the 120-count package, while NDC 71335-0569-00 is the 7 capsules package.
What NDC number is used to bill for this package of Omeprazole 20 mg Capsule, Delayed Release?
Bill NDC 71335-0569-07 — the 11-digit billing format is 71335056907. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

🧭 About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 71335-0569-7, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 71335-0569-07, written without dashes as 71335056907. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 71335-0569-07, the first segment (71335) is the labeler code FDA assigned to Bryant Ranch Prepack; the middle segment (0569) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (07) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page it is currently marketed — but Bryant Ranch Prepack has reported a marketing end date of 2027-01-31, after which this package is expected to stop being marketed. The directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 9 other package presentations of this same product, including 7 capsules (71335-0569-00), 15 capsules (71335-0569-06), 20 capsules (71335-0569-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Bryant Ranch Prepack is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients 💬 Medication Guide
🎯 Indications and Usage ~3 min read ▾

1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 )

1.1Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

1.2Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.

Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] .

1.3Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.

1.4Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older.

1.5Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given.

If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age Omeprazole is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age.

1.6Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months.

1.7Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Indication Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks ( 2.1 ) H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy : Omeprazole 20 mg Each drug twice daily for 10 days ( 2.1 )* Amoxicillin 1000 mg Clarithromycin 500 mg Dual Therapy: Omeprazole 40 mg once daily for 14 days** Clarithromycin 500 mg three times daily for 14 days ( 2.1 ) Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks ( 2.1 ) Symptomatic GERD 20 mg once daily for up to 4 weeks ( 2.1 ) See full prescribing information for weight based dosing in pediatric patients 1 year of age and older ( 2.2 ) EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks ( 2.1 )*** See full prescribing information for weight based dosing in pediatric patients 1 month of age and older ( 2.2 ) Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily ( 2.1 )****See full prescribing information for weight based dosing in pediatric patients 1 year of age and older ( 2.2 ) Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated ( 2.1 ) * if ulcer present, continue omeprazole 20 mg once daily for an additional 18 days. ** if ulcer present, continue omeprazole 20 mg once daily for an additional 14 days. *** an additional 4 weeks of treatment may be given if no response; if recurrence additional 4 to 8 week courses may be considered. **** studied for 12 months.

Reduce the dosage to 10 mg once daily for patients with hepatic impairment (Child-Pugh Class A, B, or C) and Asian patients ( 8.6 , 8.7 )

2.1Recommended Adult Dosage Regimen by Indication Table 1 shows the recommended dosage of omeprazole in adult patients by indication. Table 1: Recommended Dosage Regimen of Omeprazole in Adults by Indication Indication Dosage of Omeprazole Treatment Duration Treatment of Active Duodenal Ulcer 20 mg once daily 4 weeks1 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy Omeprazole 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three drugs twice daily 10 days In patients with an ulcer present at the time of initiation of therapy, continue omeprazole 20 mg once daily for an additional 18 days for ulcer healing and symptom relief.

Dual Therapy Omeprazole 40 mg once daily Clarithromycin 500 mg three times daily 14 days In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief. Active Benign Gastric Ulcer 40 mg once daily 4 to 8 weeks Treatment of Symptomatic GERD 20 mg once daily Up to 4 weeks Treatment of EE due to Acid- Mediated GERD 20 mg once daily 4 to 8 weeks 2 Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily 3 Controlled studies do not extend beyond 12 months.

Pathological Hypersecretory Conditions Starting dose is 60 mg once daily; adjust to patient needs Daily dosages of greater than 80 mg should be administered in divided doses. Dosages up to 120 mg three times daily have been administered. As long as clinically indicated.

Some patients with Zollinger- Ellison syndrome have been treated continuously for more than 5 years. 1. Most patients heal within 4 weeks; some patients may require an additional 4 weeks of therapy to achieve healing 2.

The efficacy of omeprazole used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole may be considered.

3. Dosage reduction to 10 mg once daily is recommended for patients with hepatic impairment (Child-Pugh Class A…

💊 Dosage Forms and Strengths 111 words ▾

3 DOSAGE FORMS AND STRENGTHS Omeprazole delayed-release capsules, USP 10 mg are hard gelatin capsules with a pink opaque body and a reddish brown opaque cap. “APO 010” is imprinted on each capsule in black ink. Omeprazole delayed-release capsules, USP 20 mg are hard gelatin capsules with a pink opaque body and a reddish brown opaque cap. “APO 020” is imprinted on each capsule in black ink. Omeprazole delayed-release capsules, USP 40 mg are hard gelatin capsules with a pink opaque body and a reddish brown opaque cap. “APO 040” is imprinted on each capsule in black ink.

Omeprazole delayed-release capsules: 10 mg, 20 mg and 40 mg ( 3 )

⛔ Contraindications 138 words ▾

4 CONTRAINDICATIONS Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions ( 7 )].

For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts. Patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation. ( 4 ) Patients receiving rilpivirine-containing products.

( 4 , 7 ) Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with omeprazole. ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Gastric Malignancy : In adults, symptomatic response does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing. ( 5.1 ) Acute Interstitial Nephritis : Observed in patients taking PPIs.

( 5.2 ) Clostridium difficile -Associated Diarrhea : PPI therapy may be associated with increased risk. ( 5.3 ) Bone Fracture : Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. ( 5.4 ) Cutaneous and Systemic Lupus Erythematosus : Mostly cutaneous; new onset or exacerbation of existing disease; discontinue omeprazole and refer to specialist for evaluation.

( 5.5 ) Interaction with Clopidogrel : Avoid concomitant use of omeprazole. ( 5.6 , 7 ) Cyanocobalamin (Vitamin B-12) Deficiency : Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin. ( 5.7 ) Hypomagnesemia : Reported rarely with prolonged treatment with PPIs.

( 5.8 ) Interaction with St. John’s Wort or Rifampin : Avoid concomitant use of omeprazole. ( 5.9 , 7 ) Interactions with Diagnostic Investigations for Neuroendocrine Tumors : Increased Chromogranin A (CgA) levels may interfere with diagnostic investigations for neuroendocrine tumors; temporarily stop omeprazole at least 14 days before assessing CgA levels.

( 5.10 , 7 ) Interaction with Methotrexate : Concomitant use with PPIs may elevate and/or prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of omeprazole. ( 5.11 , 7 ) Fundic Gland Polyps : Risk increases with long-term use, especially beyond one year.

Use the shortest duration of therapy. ( 5.12 )

5.1Presence of Gastric Malignancy In adults, symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.

5.2Acute Interstitial Nephritis Acute interstitial nephritis has been observed in patients taking PPIs including omeprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue omeprazole if acute interstitial nephritis develops [ see Contraindications ( 4 ) ].

5.3Clostridium difficile -Associated Diarrhea Published observational studies suggest that PPI therapy like omeprazole may be associated with an increased risk of Clostridium difficile -associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6.2) ]. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with omeprazole, refer to Warnings and Precautions sections of the corresponding prescribing information.

5.4Bone Fracture Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see Dosage and Administration ( 2.1 ), Advers…

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS Adults: Most common adverse reactions in adults (incidence ≥2%) are Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence. ( 6 ) Pediatric patients (1 to 16 years of age): Safety profile similar to that in adults, except that respiratory system events and fever were the most frequently reported reactions in pediatric studies. ( 8.4 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The following serious adverse reactions are described below and elsewhere in labeling: Acute Interstitial Nephritis [see Warnings and Precautions ( 5.2 )] Clostridium difficile-Associated Diarrhea [see Warnings and Precautions ( 5.3 )] Bone Fracture [see Warnings and Precautions ( 5.4 )] Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions ( 5.5 )] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions ( 5.7 )] Hypomagnesemia [see Warnings and Precautions ( 5.8 )] Fundic Gland Polyps [see Warnings and Precautions ( 5.12 )]

6.1Clinical Trials Experience with Omeprazole Monotherapy Monotherapy Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described below reflects exposure to omeprazole delayed-release capsules in 3096 patients from worldwide clinical trials (465 patients from US studies and 2,631 patients from international studies).

Indications clinically studied in US trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate ≥2%) from omeprazole-treated patients enrolled in these studies included headache (7%), abdominal pain (5%), nausea (4%), diarrhea (4%), vomiting (3%), and flatulence (3%).

Additional adverse reactions that were reported with an incidence ≥1% included acid regurgitation (2%), upper respiratory infection (2%), constipation (2%), dizziness (2%), rash (2%), asthenia (1%), back pain (1%), and cough (1%). The clinical trial safety profile in patients greater than 65 years of age was similar to that in patients 65 years of age or less. The clinical trial safety profile in pediatric patients who received omeprazole delayed-release capsules was similar to that in adult patients.

Unique to the pediatric population, however, adverse reactions of the respiratory system were frequently reported in the 1 month to <1 year age group, the 1 to <2 year age group, and the 2 to 16 year age group (42%, 75%, and 19%, respectively). In addition, otitis media was frequently reported in the 1 month to <1 year age group (22%), fever was frequently reported in the 1 to <2 year age group (33%), and accidental injuries were frequently reported in the 2 to 16 year age group (4%) [see Use in Specific Populations (8.4) ].

6.2Clinical Trials Experience with Omeprazole in Combination Therapy for H. pylori Eradication In clinical trials using either dual therapy with omeprazole and clarithromycin, or triple therapy with omeprazole, clarithromycin, and amoxicillin, no adverse reactions unique to these drug combinations were observed. Adverse reactions observed were limited to those previously reported with omeprazole, clarithromycin, or amoxicillin alone. Dual Therapy (omeprazole/clarithromycin) Adverse reactions observed in controlled clinical trials using combination therapy with omeprazole and clarithromycin (n = 346) that differed from those previously described for omeprazole alone were taste perversion (15%), tongue discoloration (2%), rhinitis (2%), pharyngitis (1%) and flu-syndrome (1%).

(For more information on clarithromycin, refer to the clarithromycin prescribing information, Adverse Reactions section.…

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable.

The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity [see Clinical Pharmacology ( 12.3 )] .

There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Rilpivirine-containing products : Concomitant use with omeprazole is contraindicated [see Contraindications ( 4 )] . Atazanavir : Avoid concomitant use with omeprazole.

See prescribing information for atazanavir for dosing information. Nelfinavir : Avoid concomitant use with omeprazole. See prescribing information for nelfinavir.

Saquinavir : See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. Other antiretrovirals : See prescribing information for specific antiretroviral drugs. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly.

Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. Methotrexate Clinical Impact: Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities.

No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted [see Warnings and Precautions ( 5.11 )] . Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Clinical Pharmacology ( 12.3 )] .

There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. Intervention: Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy [see Warnings and Precautions ( 5.6 )] .

Citalopram Clinical Impact: Increased exposure of citalopram leading to an increased risk of QT prolongation [see Clinical Pharmacology ( 12.3 )] . Intervention: Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram.

Cilostazol Clinical Impact: Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) [see Clinical Pharmacology ( 12.3 )] . Intervention: Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol.

Phenytoin Clinical Impact: Potential for increased exposure of phenytoin. Intervention: Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations.

See prescribing information for phenytoin. Diazepam Clinical Impact: Increased exposure o…

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary There are no adequate and well-controlled studies with omeprazole in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. Reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34 times an oral human dose of 40 mg (based on a body surface area for a 60 kg person).

Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with doses about 68 times and 42 times, respectively, an oral human dose of 40 mg esomeprazole or 40 mg omeprazole (based on body surface area for a 60 kg person). Changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole.

When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age [see Data] . The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H 2 -receptor antagonists or other controls. A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, from 1995 to 99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy.

The number of infants exposed in utero to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population. The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population. A population-based retrospective cohort study covering all live births in Denmark from 1996 to 2009, reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837,317 live births whose mothers did not use any proton pump inhibitor.

The overall rate of birth defects in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any proton pump inhibitor during the first trimester. A retrospective cohort study reported on 689 pregnant women exposed to either H 2 -blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester. The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H 2 -blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively.

A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% with first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non­-teratogens, and 2.8% in disease-paired controls. Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean bi…

🤰 Pregnancy ~3 min read ▾

8.1Pregnancy Risk Summary There are no adequate and well-controlled studies with omeprazole in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. Reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34 times an oral human dose of 40 mg (based on a body surface area for a 60 kg person).

Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with doses about 68 times and 42 times, respectively, an oral human dose of 40 mg esomeprazole or 40 mg omeprazole (based on body surface area for a 60 kg person). Changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole.

When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age [see Data] . The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H 2 -receptor antagonists or other controls. A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, from 1995 to 99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy.

The number of infants exposed in utero to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population. The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population. A population-based retrospective cohort study covering all live births in Denmark from 1996 to 2009, reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837,317 live births whose mothers did not use any proton pump inhibitor.

The overall rate of birth defects in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any proton pump inhibitor during the first trimester. A retrospective cohort study reported on 689 pregnant women exposed to either H 2 -blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester. The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H 2 -blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively.

A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% with first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non­-teratogens, and 2.8% in disease-paired controls. Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight were similar among…

🧒 Pediatric Use ~2 min read ▾

8.4Pediatric Use The safety and effectiveness of omeprazole have been established in pediatric patients 1 to 16 years for the treatment of symptomatic GERD, treatment of EE due to acid-mediated GERD, and maintenance of healing of EE due to acid- mediated GERD. Use of omeprazole in this age group is supported by adequate and well-controlled studies in adults and uncontrolled safety, efficacy and pharmacokinetic studies performed in pediatric and adolescent patients [see Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14.8 )] .

The safety and effectiveness of omeprazole have been established in pediatric patients 1 month to less than 1 year of age for the treatment of EE due to acid-mediated GERD and is supported by adequate and well-controlled studies in adults and safety, pharmacokinetic, and pharmacodynamic studies performed in pediatric patients [see Clinical Pharmacology ( 12.3 )] . In the pediatric population, adverse reactions of the respiratory system were frequently reported in the entire (1 month to 16 year) age group. Otitis media was frequently reported in the 1 month to <1 year age group, fever was frequently reported in the 1 to < 2 year age group, and accidental injuries were frequently reported in the 2 to 16 year age group [see Adverse Reactions ( 6.1 )] .

The safety and effectiveness of omeprazole have not been established in: patients less than 1 year of age for: Treatment of symptomatic GERD Maintenance of healing of EE due to acid-mediated GERD pediatric patients for: Treatment of active duodenal ulcer H. pylori eradication to reduce the risk of duodenal ulcer recurrence Treatment of active benign gastric ulcer Pathological hypersecretory conditions patients less than 1 month of age for any indication. Juvenile Animal Data Esomeprazole, an enantiomer of omeprazole, was shown to decrease body weight, body weight gain, femur weight, femur length, and overall growth at oral doses about 34 to 68 times a daily human dose of 40 mg esomeprazole or 40 mg omeprazole based on body surface area in a juvenile rat toxicity study.

The animal to human dose multiples are based on the assumption of equal systemic exposure to esomeprazole in humans following oral administration of either 40 mg esomeprazole or 40 mg omeprazole. A 28-day toxicity study with a 14-day recovery phase was conducted in juvenile rats with esomeprazole magnesium at doses of 70 to 280 mg/kg/day (about 17 to 68 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). An increase in the number of deaths at the high dose of 280 mg/kg/day was observed when juvenile rats were administered esomeprazole magnesium from postnatal day 7 through postnatal day 35.

In addition, doses equal to or greater than 140 mg/kg/day (about 34 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis), produced treatment-related decreases in body weight (approximately 14%) and body weight gain, decreases in femur weight and femur length, and affected overall growth. Comparable findings described above have also been observed in this study with another esomeprazole salt, esomeprazole strontium, at equimolar doses of esomeprazole.

🧓 Geriatric Use 125 words ▾

8.5Geriatric Use Omeprazole was administered to over 2000 elderly individuals (≥ 65 years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

Pharmacokinetic studies have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers. However, no dosage adjustment is necessary in the elderly [ see Clinical Pharmacology (12.3) ].

🆘 Overdosage 126 words ▾

10 OVERDOSAGE Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience [see Adverse Reactions (6) ] .

Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable.

In the event of overdosage, treatment should be symptomatic and supportive. If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

12.2Pharmacodynamics Antisecretory Activity After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H + /K + ATPase enzyme.

When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in healthy subjects and patients are shown below.

The “max” value represents determinations at a time of maximum effect (2 to 6 hours after dosing), while “min” values are those 24 hours after the last dose of omeprazole. Table 5: Range of Mean Values from Multiple Studies of the Mean Antisecretory Effects of Omeprazole After Multiple Daily Dosing Omeprazole 20 mg Omeprazole 40 mg Parameter Max Min Max Min % Decrease in Basal Acid Output 78 1 58 to 80 94 1 80 to 93 % Decrease in Peak Acid Output 79 1 50 to 59 88 1 62 to 68 % Decrease in 24-hr. Intragastric Acidity 80 to 97 92 to 94 1.

Single Studies Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric acidity in some patients. Serum Gastrin Effects In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment.

In comparison with histamine H 2 -receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.

Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors [ see Warnings and Precautions ( 5.10 ) ]. Enterochromaffin-like (ECL) Cell Effects Human gastric biopsy specimens have been obtained from more than 3,000 patients (both children and adults) treated with omeprazole in long-term clinical trials.

The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions. Other Effects Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.

Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol…

🧬 Mechanism of Action 94 words ▾

12.1Mechanism of Action Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

📦 How Supplied / Storage and Handling ~1 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Omeprazole delayed-release capsules, USP 20 mg are available for oral administration as hard gelatin capsules with a pink opaque body and a reddish-brown opaque cap. “APO 020” is imprinted on each capsule in black ink. They are supplied as follows: NDC: 71335-0569-0 7 CAPSULE in a BOTTLE NDC: 71335-0569-1 30 CAPSULE in a BOTTLE NDC: 71335-0569-2 60 CAPSULE in a BOTTLE NDC: 71335-0569-3 56 CAPSULE in a BOTTLE NDC: 71335-0569-4 90 CAPSULE in a BOTTLE NDC: 71335-0569-5 20 CAPSULE in a BOTTLE NDC: 71335-0569-6 15 CAPSULE in a BOTTLE NDC: 71335-0569-7 120 CAPSULE in a BOTTLE NDC: 71335-0569-8 100 CAPSULE in a BOTTLE NDC: 71335-0569-9 28 CAPSULE in a BOTTLE Omeprazole delayed-release capsules, USP 40 mg are available for oral administration as hard gelatin capsules with a pink opaque body and a reddish-brown opaque cap. “APO 040” is imprinted on each capsule in black ink.

They are supplied as follows: NDC: 71335-1395-1 60 CAPSULE in a BOTTLE NDC: 71335-1395-2 30 CAPSULE in a BOTTLE NDC: 71335-1395-3 20 CAPSULE in a BOTTLE NDC: 71335-1395-4 90 CAPSULE in a BOTTLE NDC: 71335-1395-5 14 CAPSULE in a BOTTLE NDC: 71335-1395-6 120 CAPSULE in a BOTTLE NDC: 71335-1395-7 100 CAPSULE in a BOTTLE NDC: 71335-1395-8 180 CAPSULE in a BOTTLE Storage Store omeprazole delayed-release capsules in a tight container protected from light and moisture. Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

📋 Description ~1 min read ▾

11 DESCRIPTION The active ingredient in omeprazole delayed-release capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 17 H 19 N 3 O 3 S, with a molecular weight of 345.42 g/mol. The structural formula is: Omeprazole is a white to off-white crystalline powder that melts with decomposition at about 155°C.

It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions. Omeprazole Delayed-Release Capsules meet USP Dissolution Test 2.

Omeprazole is supplied as delayed-release capsules for oral administration. Each delayed-release capsule contains either 10 mg, 20 mg or 40 mg of omeprazole in the form of enteric-coated granules with the following inactive ingredients: magnesium hydroxide, mannitol, methacrylic acid copolymer dispersion, povidone and triethyl citrate. The capsule shells have the following inactive ingredients: D&C Red No.

28*, D&C Red No.33*, D&C Yellow No. 10*, FD&C Blue No. 1*, FD&C Red No.

40*, gelatin, iron oxide red* and titanium dioxide (*contains one or more of these ingredients). The capsule imprinting ink contains ammonium hydroxide, black iron oxide, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, potassium hydroxide, propylene glycol and shellac. chemical-structure

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Adverse Reactions Advise patients to report to their healthcare provider if they experience any signs or symptoms consistent with: Hypersensitivity reactions [see Contraindications ( 4 )] . Acute Interstitial Nephritis [see Warnings and Precautions ( 5.2 )] .

Clostridium difficile -Associated Diarrhea [see Warnings and Precautions ( 5.3 )] . Bone Fracture [see Warnings and Precautions ( 5.4 )] . Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions ( 5.5 )] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions ( 5.7 )] .

Hypomagnesemia [see Warnings and Precautions ( 5.8 )] . Drug Interactions Advise patients to report to their healthcare provider if they start treatment with clopidogrel, St. John’s Wort or rifampin; or, if they take high-dose methotrexate [see Warnings and Precautions ( 5.6 , 5.9 , 5.11 )] .

Administration Take omeprazole before meals. Antacids may be used concomitantly with omeprazole. Missed doses: If a dose is missed, administer as soon as possible.

However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time. Do not take two doses at one time to make up for a missed dose. Omeprazole Delayed-Release Capsules Swallow omeprazole delayed-release capsules whole; do not chew.

For patients unable to swallow an intact capsule, omeprazole delayed-release capsules can be opened and administered in applesauce, as described in the Medication Guide. APOTEX INC. OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP 10 mg, 20 mg and 40 mg Manufactured by Manufactured for Apotex Inc.

Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 USA 33326 Revised: May 2018 Revision: 23

💬 Medication Guide ~3 min read ▾

MEDICATION GUIDE Omeprazole Delayed-Release Capsules, USP (oh mep’ ra zole) Read this Medication Guide before you start taking omeprazole delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.

What is the most important information I should know about omeprazole delayed-release capsules? Omeprazole delayed-release capsules may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.

Omeprazole delayed-release capsules can cause serious side effects, including: A type of kidney problem (acute interstitial nephritis). Some people who take proton pump inhibitor (PPI) medicines, including omeprazole, may develop a kidney problem called acute interstitial nephritis that can happen at any time during treatment with omeprazole. Call your doctor if you have a decrease in the amount that you urinate or if you have blood in your urine.

Diarrhea . Omeprazole may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection ( Clostridium difficile ) in your intestines.

Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away. Bone fractures . People who take multiple daily doses of PPI medicines for a long period of time (a year or longer) may have an increased risk of fractures of the hip, wrist, or spine.

You should take omeprazole delayed-release capsules exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone fracture if you take omeprazole delayed-release capsules. Certain types of lupus erythematosus.

Lupus erythematosus is an autoimmune disorder (the body’s immune cells attack other cells or organs in the body). Some people who take proton PPI medicines, including omeprazole, may develop certain types of lupus erythematosus or have worsening of the lupus they already have. Call your doctor right away if you have new or worsening joint pain or a rash on your cheeks or arms that gets worse in the sun.

Omeprazole can have other serious side effects. See “What are the possible side effects of omeprazole delayed-release capsules?” What are omeprazole delayed-release capsules? Omeprazole delayed-release capsules is a prescription medicine called a proton pump inhibitor (PPI).

Omeprazole delayed-release capsules reduces the amount of acid in your stomach. Omeprazole delayed-release capsules are used in adults: for up to 8 weeks for the healing of duodenal ulcers. The duodenal area is the area where food passes when it leaves the stomach. with certain antibiotics for 10 to 14 days to treat an infection caused by bacteria called H. pylori.

If needed, your doctor may decide to prescribe another 14 to 18 days of omeprazole by itself after the antibiotics. Sometimes H. pylori bacteria can cause duodenal ulcers. The infection needs to be treated to prevent the ulcers from coming back. for up to 8 weeks for healing stomach ulcers. for up to 4 weeks to treat heartburn and other symptoms that happen with gastroesophageal reflux disease (GERD).

GERD happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping. for up to 8 weeks to heal acid-related damage to the lining of the esophagus (called erosive esophagitis or EE). If needed, your doctor may decide to prescribe another 4 weeks of omeprazole delayed-release capsules. to maintain healing of the esophagus.

It is not known if omeprazole delayed-release capsules is safe and effective when used for longer than 12 months (1 year) for this purpose. for the long-term treatment of conditions where your stomach makes too much acid. This includes a rare condition called Zollinger-Ellison Syndrome. For children 1 to 16 y…

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 71335-0567-01 · Bryant 71335-0574-01 · Bryant →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.